Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENEO neoadjuvant docetaxel + cetuximab pilot phase II study in triple-negative operable breast cancer
2007-002371-13Phase 2Active
- Sponsor
- Centre Jean Perrin
- Start
- Aug 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and cetuximab in triple-negative breast cancer (TNBC) and Infiltrating Ductal Carcinoma (IDC), sponsored by Centre Jean Perrin. Primary endpoint: Pathologic complete response. Started Aug 2007; status: active.
02
Drugs
docetaxelcetuximab
03
Conditions
triple-negative breast cancer (TNBC)Infiltrating Ductal Carcinoma (IDC)
Beyond the preview
Go deeper on 2007-002371-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002371-13.